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Available online xxxxObjective.: The immune-inﬂammatory system has been implicated in the pathogenesis of diabetic nephrop-
athy; however, many of the mechanisms involved remain unclear. Chitotriosidase enzyme is an active human
chitinase and a major protein product of activated macrophages. Although playing an important role in innate
and acquired immunity, chitotriosidase involvement in the development of diabetic nephropathy is unknown.
Design and methods.: Chitotriosidase enzyme activity and the presence of the functional 24-bp duplication
mutation of the chitotriosidase gene (CHIT1) were assessed in 262 Egyptian type 2 diabetic patients with and
without nephropathy and 90 non-diabetic controls. In diabetic patients, multiple linear regression models
were adapted to assess the association of chitotriosidase activity with two important measures of renal disease
progression: urinary albumin/creatinine ratio and eGFR, while the association of the CHIT1 genotypewith the in-
cidence of nephropathy was evaluated by multiple logistic regression.
Results: In diabetic patients, chitotriosidase enzyme activity showed a statistically signiﬁcant elevation as
compared to controls and correlated positively with the progression of nephropathy. A signiﬁcant association
of chitotriosidase activity with both urinary albumin/creatinine ratio and eGFR was detected after adjusting for
age, gender, duration of diabetes, body mass index, hypertension status, total cholesterol, triglycerides and
HbA1c levels, P b 0.001.We also identiﬁed a protective association between the CHIT1mutated genotype and di-
abetic nephropathy after adjusting for the same confounders (odds ratio: 0.517, 95% CI: 0.289–0.924, P= 0.026).
Conclusions: This studydemonstrates for theﬁrst time that the immunomodulatory effects of chitotriosidase
enzyme could be implicated in the development of nephropathy in type 2 diabetes.
© 2015 The Canadian Society of Clinical Chemists. Published by Elsevier Inc. All rights reserved.Keywords:
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Diabetic nephropathy is an importantmicrovascular complication of
diabetesmellitus and themost common cause of end stage renal disease
(ESRD) [1]. About 20 to 40% of patients with type 1 or type 2 diabetes
develop evidence of nephropathy and for type 2 less than 40% of those
will progress to ESRD [2]. The development of diabetic nephropathy is
a very complex process affected by age, ethnicity, duration of diabetes,
glycemic control status, associated hypertension, life style factors and
multiple genetic predispositions [3,4]. Many studies including in-vitro
cellular experiments, animal model experiments and epidemiological
studies linked inﬂammation to pathogenic mechanisms in diabeticn, chronic kidney disease epide-
ease; eGFR, estimated glomeru-
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.org/10.1016/j.clinbiochem.20nephropathy [5]. Macrophage migration and recruitment, especially
M1 subpopulations, directly contribute to renal injury in diabetes, per-
haps by altering podocyte integrity [6] and directly correlate with the
degree of renal ﬁbrosis [7]. Furthermore, several immunomodulatory
molecules such as chemokines (CCL2, CX3CL1 and CCL5), adhesionmol-
ecules (intercellular adhesionmolecule 1, vascular cell adhesion protein
1, E-selectin andα-actinin 4), and cytokines (IL-1, IL-6, IL-18 and tumor
necrosis factor-α) have all been implicated in the pathogenesis of dia-
betic nephropathy [5].
Chitotriosidase enzyme is a fully active human chitinase that was
initially discovered to be markedly elevated in the plasma of patients
with Gaucher's disease, an inﬂammatory-based lysosomal storage
disorder [8]. Later, its elevation was detected in other lysosomal and
non-lysosomal inﬂammatory disorders [9–12]. Chitotriosidase is
both an endo- and exo-chitinase splitting chitin molecules into
smaller polysaccharide moieties and also to its basic monosaccha-
ride N-acetylglucosamine [13]. The absence of its substrate chitin
in mammals and the exclusive expression in immune cells, mainly
activated macrophages, elucidated its involvement in the activationhts reserved.
e enzyme activity and genotypewith the risk of nephropathy in type 2
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tin coated pathogens [13,14]. Many immune enhancing molecules
such as tumor necrosis factor-α, interferon-γ and lipopolysaccha-
ride promote chitotriosidase expression in activated macrophages
[15], while chitotriosidase was shown to stimulate IL8, CCL2, CCL5
and eotaxin and to increase the migratory capacity of eosinophils,
T lymphocytes and macrophages [16]. Chitotriosidase also stimu-
lates transforming growth factor-β1 receptor expression and signal-
ing suggesting a role in enhancing the response to organ injury and
repair. For example, bleomycin-induced pulmonary ﬁbrosis was sig-
niﬁcantly reduced in chitotriosidase null mice and signiﬁcantly en-
hanced in chitotriosidase over-expressing transgenic mice [17].
The 24-bp duplication mutation (rs3831317) at exon ten of the
chitotriosidase gene (CHIT1), resulting in aberrant splicing and deletion
of 87 nucleotides, is the main cause of complete enzyme deﬁciency in
about 6% of Caucasians when homozygously mutated. It also reduces
the chitotriosidase enzyme expression in heterozygous individuals
[18]. In this cross-sectional study we aimed to investigate the potential
role of chitotriosidase enzyme and its functionalmutation (24-bp dupli-
cation) in the development and progression of nephropathy in a cohort
of Egyptian type 2 diabetic patients.2. Patients and methods
2.1. Patients
For the current study, 262 Egyptian type 2 diabetic patients (48.6 ±
5 y, 42.3% males) for a minimum duration of ten years, and 90 non-
diabetic controls (43.5 ± 4.7 y, 38.9% males) were recruited from pa-
tients presenting to the internal medicine and nephrology outpatient
clinics at Theodor Bilharz research institute (TBRI) and blood donors
visiting the blood bank at TBRI, respectively. Enrolment of patients ex-
tended over the period from October 2013 to December 2014. Diabetic
patients were further divided into patients without diabetic nephropa-
thy evidenced by urinary albumin excretion b3.4 mg/mmol creatinine
(n = 84, 47.4 ± 5.2 y) and patients with diabetic nephropathy (n =
178, 49.3 ± 4.7 y), presenting with either microalbuminuria (3.4–34
mg/mmol creatinine, n = 88, 47.8 ± 4.1 y) or macroalbuminuria (N34
mg/mmol creatinine, n = 90, 51 ± 4.6 y). Body mass index (BMI) in
control subjects was matching type 2 diabetic patients.
Demographic and clinical data were recorded including age, gender,
BMI, duration of diabetes andhistory of previous episodes ofmyocardial
infarction or stroke. Associated hypertension was determined based on
blood pressure levels over 140/90mmHg or the intake of antihyperten-
sive medications, while the presence of other microvascular complica-
tions such as retinopathy and/or neuropathy was based on standard
fundoscopy and neurological examinations, respectively. Routine labo-
ratory investigations including fasting plasma glucose, urea, creatinine,
urinary albumin creatinine ratio, total bilirubin, alanine transaminase,
total cholesterol, triglycerides, HDL-cholesterol and LDL-cholesterol
were assayed by Synchron CX5 (Beckman Coulter, Brea, California,
USA). HbA1cwas assayed by the ion-exchange resin separationmethod
(Human Diagnostics, Wiesbaden, Germany). Estimated GFR (eGFR)
calculation was based on the chronic kidney disease epidemiology
collaboration (CKD-EPI) equation. [GFR = 141 × min(Scr/κ, 1)α ×
max(Scr/κ, 1)−1209 × 0.993Age × 1018 (if female) × 1159 (if black)],
where Scr = serum creatinine, κ = 0.7 if female and 0.9 if male,
α = −0.329 if female and −0.411 if male, min = the minimum of
Scr/κ or 1 and max = the maximum of Scr/κ or 1 [19].
Diabetic patients with hepatic disease, heart failure, neurological or
other endocrinological diseases, cancers or any acute or chronic infec-
tions were excluded from the study. A written informed consent was
obtained from all diabetic patients and non-diabetic controls. The
study protocol was in accordance with the declaration of Helsinki
1975 and asmodiﬁed in 2012, and approved by the institutional reviewPlease cite this article as:M.A. Elmonem, et al., Association of chitotriosidas
diabetes, Clin Biochem (2015), http://dx.doi.org/10.1016/j.clinbiochem.20board of TBRI before the start of enrolling participants (Reference
number: FWA 00010609).
2.2. Chitotriosidase enzyme activity
Plasma chitotriosidase activity was measured as described previously
[20]. Ten microliters of plasma were mixed with 100 μL of 0.022 mmol/l
4-methylumbelliferyl-β-D-N,N′,N″-triacetylchitotrioside (Sigma) in cit-
rate/phosphate buffer, 0.1/0.2 mol/L, pH 5.2 and incubated at 37 °C for
15min. The reactionwas stoppedwith 2mL of 0.5mol/L carbonate/bicar-
bonate buffer, pH 10.7. Fluorescence wasmeasured by FP 6200 (Jasco an-
alytical instruments, Tokyo, Japan) at excitation wavelength 365 nm and
emissionwavelength 448nm. Enzyme activitieswere calculated based on
a calibration curve of 4-methylumbelliferone and expressed as nmol of
enzyme product formed/mL plasma/h.
2.3. Chitotriosidase genotype
DNAwas extracted from EDTA blood using the GeneJET DNA puriﬁ-
cation kit (Thermo Scientiﬁc, MA, USA) according to themanufacturer′s
protocol. The detection of the 24-bp duplication mutation within exon
ten of CHIT1 gene was performed as previously described [18]using
the primers 5′-AGCTATCTGAAGCAGAAG-3′ and 5′-GGAGAAGCCGGC
AAAGTC-3′ as forward and reverse primers, respectively. PCR protocol
constituted of initial denaturation at 95 °C for 3 min followed by 35 cy-
cles of: denaturation at 95 °C for 30 s, annealing at 56 °C for 60 s, exten-
sion at 72 °C for 30 s and ﬁnal extension at 72 °C for 7 min. Detection of
PCR ampliﬁcation products was performed using either 4% agarose or
10% polyacrylamide gel electrophoresis, ethidium bromide as a staining
dye and ultraviolet transillumination; revealing the formation of a
75-bp band in the wild-type, a 99-bp band in the homozygously mutat-
ed and both in the heterozygous. Genotype assessment was repeated in
a random sample consisting of 25% of all subjects.
2.4. Statistical analysis
Comparisons of quantitative data were analyzed using Mann–
WhitneyU-test or Kruskal–Wallis test for differences betweenmedians.
Pearson chi-square (χ2) test was used to test categorical variables
among groups and also to test the Hardy–Weinberg equilibrium for
the mutation genotype and allele frequencies among controls and
patients. Association of chitotriosidase enzyme activities with the con-
tinuous variables urinary albumin/creatinine ratio and estimated GFR
was performed through multiple linear regression after adjusting for
age, gender, BMI, duration of diabetes, hypertension status, total choles-
terol, triglycerides and HbA1c levels. The 24-bp duplication mutation
was also associated with the dichotomous variable diabetic nephropa-
thy through multiple logistic regression adjusted for the same con-
founders. Associations were expressed as regression coefﬁcients with
standard errors for linear regressions and as odds ratios with 95% conﬁ-
dence intervals (CI) for logistic regressions. A 2-sided P value b 0.05was
considered signiﬁcant. Sample size calculation was based on prelimi-
nary data obtained from a pilot study performed in 50 type 2 Egyptian
diabetic patients, whose data are not included in the current study.
Statistical analysis was performed by the WINPEPI statistical software
package, version 11.43 [21].
3. Results
The study sample consisted of 262 Egyptian type 2 diabetic patients
and 90 non-diabetic controls. Demographic, clinical and biochemical
data of study participants are summarized in Table 1. Chitotriosidase
enzyme activities (median; 25th–75th percentiles) were signiﬁcantly
elevated in diabetic patients (53; 30–96 nmol/mL plasma/h) as com-
pared to non-diabetic controls (37; 31–46 nmol/mL plasma/h), P b
0.001. Furthermore, there was a signiﬁcant increase in chitotriosidasee enzyme activity and genotypewith the risk of nephropathy in type 2
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Table 1
Demographic, clinical and biochemical characteristics of studied groups.
Non-diabetic controls
(n = 90)
Diabetic patients
(n = 262)
P value Diabetic patients with
normoalbuminuria
(n = 84)
Diabetic patients with
microalbuminuria
(n = 88)
Diabetic patients with
macroalbuminuria
(n = 90)
P value
Age (years) 43; 40–47 48; 45–51.8 b0.001 47; 43–50.3 47.5; 45–50 50; 48–54 b0.001
Gender (% male) 38.9% 42.3% 0.563 33.3% 46.6% 46.7% 0.127
BMI (kg/m2) 28; 26–29 27; 26–29 0.522 27; 26–29 27; 26–29 28; 26–30 0.082
Diabetes duration (years) 16; 14–19 15; 11–17 15; 13–17 19; 17–20 b0.001
Hypertension (%) 48.8% 40.5% 44.3% 61.1% 0.014
MI or stroke (%) 45% 39.3% 38.6% 66.7% b0.001
Retinopathy (%) 33.2% 28.6% 32% 38.9% 0.308
Neuropathy (%) 55.3% 38.1% 45.5% 81.1% b0.001
FBG (mmol/L) 5.1; 4.7–5.4 9.9; 8.6–12.1 b0.001 9.8; 8.6–11.1 9.8; 8.9–12.6 10; 8.6–11.4 0.392
HbA1c (mmol/mol) 35.5; 31.1–38.8 96.7; 80.3-113.1 b0.001 85.8; 74.9–107.7 97.8; 81.4–108.8 103.3; 85.8–127.3 0.001
(%) 5.4; 5–5.7 11; 9.5–12.5 10; 9–12 11.1; 9.6–12.1 11.6; 10–13.8
Urea (mmol/L) 4.2; 3.2–5.3 10.5; 4.5–20 b0.001 4.5; 3.5–6.2 6.2; 4.5–10.8 22.5; 17.8–26.7 b0.001
Creatinine (μmol/L) 62; 53–71 88; 62–292 b0.001 63; 53–73 88;71–107 451; 274–743 b0.001
eGFR (mL/min/1.73m2) 109; 101–118 70; 19–105 b0.001 106; 96–114 87; 60–102 11; 6–20 b0.001
Urinary ACR (mg/mmol) 0.31; 0.2–0.71 8.5; 1.2–41.6 b0.001 0.51; 0.21–1.1 8.1; 5.9–12.8 51.9; 40.8–67.6 b0.001
ALT (U/L) 19; 15–22 21; 17–29 b0.001 20; 16–27 22; 17–28 22; 17–29 0.711
Total bilirubin (μmol/L) 12; 9.1–15.4 12; 10.3–15.4 0.27 10.3; 10.2–13.7 12; 10.3–15.4 13.7; 10.3–16.8 0.026
Total cholesterol (mmol/L) 5.17; 4.71–5.56 5.07; 4–6.1 0.304 4.71; 3.7–5.77 5.07; 4.1–6.05 5.17; 4.11–6.57 0.160
Triglycerides (mmol/L) 1.87; 1.64–2.03 1.8; 1.64–2.25 0.342 1.8; 1.68–2.24 1.81; 1.64–2.26 1.81; 1.64–2.25 0.943
HDL-cholesterol (mmol/L) 1.4; 1.24–1.45 1.2; 1.06–1.32 b0.001 1.22; 1.11–1.32 1.2; 1.03–1.29 1.18; 1.03–1.37 0.496
LDL-cholesterol (mmol/L) 3.03; 2.5–3.23 2.95; 1.9–3.83 0.292 2.72; 1.68–3.6 2.8; 2.02–3.83 3; 2.09–4.47 0.100
Chitotriosidase
(nmol/mL/h)
37; 31–46 53; 30–96 b0.001 30; 20–49 53; 33–90 86; 65–165 b0.001
Data are expressed asmedian; 25th–75th percentiles for quantitative variables or as % for categorical variables. Hypertension status was deﬁned as blood pressure over 140/90mmHg or
obtained from self-reporting of anti-hypertensivemedications. Previous episodes ofmyocardial infarction or stroke were based on self-reporting. Retinopathywas based on characteristic
changes in fundus examination performed by an ophthalmologist. Neuropathywas diagnosed by reduced sensation tomonoﬁlament or tuning fork and altered sensations in lower limbs.
Urinary ACR, urinary albumin/creatinine ratio. P values were obtained byMann–WhitneyU-test or Kruskal–Wallis test for quantitative data, and by Pearson chi-square test for categorical
data. Signiﬁcance was set at P b 0.05 based on a 2-sided test.
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phropathy status: normoalbuminuria (30; 20–49 nmol/mL plasma/h),
microalbuminuria (53; 33–90 nmol/mL plasma/h) and macroal-
buminuria (87; 56–165 nmol/mL plasma/h), P b 0.001 (Fig. 1).
Chitotriosidase levels also correlated signiﬁcantly with the estimates
of progression of kidney disease in diabetic patients performed in our
study. The strongest correlation was with urinary albumin creatinine
ratio (r = 0.783), followed by eGFR (r = −0.423), creatinine (r =
0.392) and urea (r= 0.305), P b 0.001 for each of them. Chitotriosidase
activities also correlated with the duration of diabetes (r = 0.179, P =
0.003). Furthermore, chitotriosidase independently predicted bothFig. 1. Box and whisker plot of chitotriosidase enzyme activities in non-diabetic controls
and different groups of type 2 diabetic patients. Vertical line represents range from 5th
to 95th percentiles, solid box represents range from 25th to 75th percentiles and horizon-
tal line represents median. DM Normo, normoalbuminuric type 2 diabetics (urinary
albumin/creatinine ratio b 3.4 mg/mmol creatinine); DM Micro, Microalbuminuric type
2 diabetics (urinary albumin/creatinine ratio 3.4–34 mg/mmol creatinine); DM Macro,
Macroalbuminuric type 2 diabetics (urinary albumin/creatinine ratio N 34 mg/mmol
creatinine). *P b 0.05 and **P b 0.001 compared to non-diabetic controls.
Please cite this article as:M.A. Elmonem, et al., Association of chitotriosidas
diabetes, Clin Biochem (2015), http://dx.doi.org/10.1016/j.clinbiochem.20albumin creatinine ratio and eGFR in the ﬁtted multiple linear regres-
sionmodels after adjustment for the confounders: Age, gender, BMI, du-
ration of diabetes, hypertension status, total cholesterol, triglycerides
and HbA1c levels, P b 0.001 for both. Table 2 summarizes the results
of the linear regression models performed. There was no direct correla-
tion between chitotriosidase levels and other quantitative clinical or
laboratory measures such as: age, BMI, fasting plasma glucose, HbA1c,
ALT, total bilirubin, total cholesterol, triglycerides, HDL-cholesterol and
LDL-cholesterol.
The genotypic and allelic frequencies of the investigated 24-bp
duplication mutation in control subjects and in diabetic patients are
summarized in Table 3. They were all in accordance with the Hardy–
Weinberg equilibrium. Thewild genotypewas detectedmore common-
lywith higher renal damage in diabetic patients, while themutatedwas
more associated with a lower renal damage. Using the Pearson χ2 test a
signiﬁcant difference existed between the three diabetic groups for
both genotypic and allelic frequencies (P = 0.007 and P = 0.009,
respectively).
In the multiple logistic regression model (Table 4), the 24-bp dupli-
cation mutation genotype (Wt/Dup and Dup/Dup) was an independent
negative predictor of the onset of nephropathy in type 2 diabetic pa-
tients after adjustment for the same confounders mentioned previously
(OR: 0.517, 95% CI: 0.289–0.924, P = 0.026). Diabetic nephropathy also
associated negatively with female gender (P= 0.045), while there was
a positive association with multiple independent factors such as: dura-
tion of diabetes (P= 0.009), total cholesterol (P= 0.012), triglycerides
(P= 0.017) and HbA1C levels (P= 0.035). When diabetic retinopathy,
neuropathy or macrovascular complications were set as the dependent
variable in the logistic regression model, no signiﬁcant association was
detected between the tested genotype and any of these complications.4. Discussion
In the current study we evaluated the association of chitotriosidase
enzyme and its loss of function mutation (24-bp duplication) with thee enzyme activity and genotypewith the risk of nephropathy in type 2
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Table 2
Multiple linear regression analysis of the relation of chitotriosidase enzyme activity to uri-
nary albumin/creatinine ratio and eGFR.
Variable β± SE of β P
value
A.Dependent: urinary albumin/creatinine ratio
Independent Age −0.656 ± 3.689 0.859
Gender (0 = male, 1 = female) 4.744 ± 21.648 0.827
BMI 3.830 ± 4.450 0.390
Diabetes duration 10.721 ± 4.342 0.014
Hypertension (0 = absent;
1 = present)
−21.65 ± 27.078 0.425
Total cholesterol 0.118 ± 0.189 0.533
Triglycerides 0.076 ± 0.175 0.664
HbA1c 3.192 ± 3.959 0.806
Chitotriosidase activity 3.067 ± 0.156 b0.001
B.Dependent: eGFR
Independent Age −0.309 ± 0.768 0.688
Gender (0 = male, 1 = female) −3.770 ± 4.494 0.402
BMI 1.232 ± 0.924 0.148
Diabetes duration −3.152 ± 0.901 b0.001
Hypertension (0 = absent;
1 = present)
−5.137 ± 5.622 0.362
Total cholesterol −0.094 ± 0.039 0.017
Triglycerides −0.078 ± 0.036 0.032
HbA1c −0.693 ± 0.822 0.400
Chitotriosidase activity −0.221 ± 0.032 b0.001
β, regression coefﬁcient; SE, standard error.
Table 4
Multiple logistic regression analysis of the relation of the CHIT1 24-bp duplication muta-
tion to diabetic nephropathy.
Variable OR (95% CI) P
value
Dependent: diabetic nephropathy (0 = absent; 1 = present)
Independent Age 0.978 (0.882–1.084) 0.672
Gender (0 = male, 1 = female) 0.542 (0.297–0.986) 0.045
BMI 0.937 (0.826–1.062) 0.307
Diabetes duration 1.175 (1.040–1.326) 0.009
Hypertension (0 = absent;
1 = present) 1.376 (0.654–2.894) 0.401
Total cholesterol 1.008 (1.002–1.017) 0.012
Triglycerides 1.007 (1.001–1.013) 0.017
HbA1c 1.137 (1.009–1.281) 0.035
24-bp duplication (0 = absent;
1 = present)
0.517 (0.289–0.924) 0.026
OR, odds ratio; CI, conﬁdence interval.
4 M.A. Elmonem et al. / Clinical Biochemistry xxx (2015) xxx–xxxrisk of development and progression of nephropathy in a large cohort of
type 2 diabetic patients.
Being an active chitinase, the wild type and fully active human
chitotriosidase enzyme is essential for the resistance against many chi-
tin coated pathogens such as Plasmodium falciparum [22], Wuchereria
bancrofti [23], Cryptococcus neoformans and Candida albicans [24]. This
is evidenced by the almost complete absence of the 24-bp duplication
mutation of CHIT1 gene in sub-Saharan Africa (0–2% of individuals)
conﬁrming the evolutionary advantage of the wild type enzyme in
areas with high endemic and parasitic disease loads [25]. On the other
hand, the high prevalence of the mutated genotype in European coun-
tries (30–40% of individuals) with much lower rates of endemic and
parasitic diseases [18,25] must also point to a different evolutionary ad-
vantage for the mutated. For example, it is well known that individuals
of African ancestry are more prone to develop nephropathy and ESRD
complicating diabetes or other different pathological conditions. This
is regardless of social status or the level of health care coverage
supporting the role of genetic predisposition in the development and
progression of kidney disease in this ethnic group [26]. Could this be re-
lated, at least partially, to the abundance of the wild type CHIT1 gene
in African populations compared to Caucasians? This is yet to be
determined.
Furthermore, chitotriosidase genotype has been linked to the patho-
genesis ofmany other inﬂammatory based conditions. Di Rosa et al. elu-
cidated the protective role of the 24-bp duplication mutation of theTable 3
Frequencies of wild type and mutant genotypes and alleles in control subjects and differ-
ent diabetic groups.
Genotype frequency Allele frequency
Wt Wt/dup Dup/dup Wt Dup
Controls (n = 90) 53 (58.9%) 33 (36.7%) 4 (4.4%) 139 (77.2%) 41 (22.8%)
Normoalbuminuria
(n = 84)
41 (48.8%) 37 (44.0%) 6 (7.2%) 119 (70.8%) 49 (29.2%)
Microalbuminuria
(n = 88)
54 (61.4%) 29 (32.9%) 5 (5.7%) 137 (77.8%) 39 (22.2%)
Macroalbuminuria
(n = 90)
65 (72.2%) 22 (24.5%) 3 (3.3%) 152 (84.4%) 28 (15.6%)
Wt, wild type; Dup, 24-bp duplication mutation.
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in Italian population [27]. In another study, Kim et al. associated the gain
of function mutation (A442G) in the CHIT1 gene with a higher risk of
atopy in Korean children [28]. Malguarnera et al. also associated the
24-bp duplication heterozygous genotype positively with human
longevity in three Mediterranean populations (Italian, Greek and
Tunisian) [29]. Denoting in accordance with the current study results
that limiting chitotriosidase expression might be beneﬁcial in more
than one aspect.
Few studies have previously explored the correlation of chito-
triosidase enzyme with diabetes. Sonmez et al. correlated chitotrio-
sidase activity with the asymmetric dimethyl arginine levels in plasma
of newly diagnosed and uncomplicated patients with type 2 diabetes
and concluded that chitotriosidase enzyme could be a predictor of
endothelial dysfunction in those patients [30]. Kabaroğlu et al. further
conﬁrmed that chitotriosidase levels were signiﬁcantly higher in
obese adolescents with glucose intolerance compared to a matched
group with normal glucose tolerance [31]. Elmonem et al. detected sig-
niﬁcant elevations of chitotriosidase levels in diabetic patients with
renal impairment versus healthy individuals when both groups were
taken as comparators for a cohort of nephropathic cystinosis patients
[10]. Recently, Żurawska-Płaksej et al. also showed that chitotriosidase
activity together with the concentration of another member of the 18
glycosyl hydrolase protein family (YKL-40) correlated with the degree
of renal insufﬁciency in type 2 diabetic subjects [32]. In the current
study, we conﬁrmed our previous results [10] and the results of
Żurawska-Płaksej et al. [32] in a much bigger cohort (almost triple)
and we further elucidated the role of the functional 24-bp duplication
mutation in decreasing the risk of developing nephropathy in type 2
diabetic patients suggesting an important role played by chitotriosidase
in the pathogenesis of diabetic nephropathy.
The fact that chitotriosidase levels were not signiﬁcantly different
between non-diabetic controls and normoalbuminuric diabetic patients
in our study (Fig. 1) denotes that the enzyme levels are mostly associat-
ed with the onset of glomerular insult rather than the earlier tubular
phase of the disease. This might be explained by the timing of inﬂux
of inﬂammatory cells to the renal parenchyma which is usually shortly
preceding the glomerular insult [6,7].
An important limitation of our study is lacking the smoking history
input into the regression models performed. Several previous studies
associated smoking and oxidative stress propagated by smoking to the
development of nephropathy in diabetic patients [33,34]. The preva-
lence of smoking in the Egyptian community is by far higher in males
than females, as it is considered sort of socially and ethically unaccept-
able behavior for females. We believe that it is highly unlikely that
smoking will affect the strong association between chitotriosidase
genotype and activity with the onset and progression of diabetice enzyme activity and genotypewith the risk of nephropathy in type 2
15.11.009
5M.A. Elmonem et al. / Clinical Biochemistry xxx (2015) xxx–xxxnephropathy detected in our study, but itmight confound the female gen-
der protective role detected in the logistic regression model (Table 4).
In conclusion, we conﬁrmed for the ﬁrst time the strong association
between chitotriosidase enzyme activity and themarkers of progressive
kidney disease in a large cohort of type 2 diabetic patients. We also
demonstrated that diabetic patients genetically lacking the full active
enzyme (with at least one CHIT1 functionally mutated allele) are at
lower risk of developing nephropathy compared to patients having
the wild genotype. Both ﬁndings strongly implicate chitotriosidase in-
volvement in the pathogenic pathway leading to the development and
progression of nephropathy in type 2 diabetic patients.
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